CN112999333A - Application of multi-target blocking peptide in preventing and treating new coronavirus infection - Google Patents
Application of multi-target blocking peptide in preventing and treating new coronavirus infection Download PDFInfo
- Publication number
- CN112999333A CN112999333A CN202110155487.0A CN202110155487A CN112999333A CN 112999333 A CN112999333 A CN 112999333A CN 202110155487 A CN202110155487 A CN 202110155487A CN 112999333 A CN112999333 A CN 112999333A
- Authority
- CN
- China
- Prior art keywords
- target blocking
- new coronavirus
- target
- preventing
- blocking peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Use of multi-target blocking peptides for the prevention and treatment of new coronavirus infections, including multi-target blocking peptides targeting APP, LDLR and LRP, namely: AY51, the application of modified amino acid sequence of multi-target blocking peptide and its lysine and C-16 fatty acid in preventing and treating SARS-CoV-2 infection of new coronavirus, and simultaneously, the detection of these fused polypeptides from molecular, cell and animal level can block the interaction of SARS-CoV-2-S protein RBD and various receptors on its cell membrane, and finally the multi-target blocking virus invades target cell to achieve the purpose of preventing and treating infection of new coronavirus.
Description
Technical Field
The invention relates to a synthetic protein polypeptide medicament, in particular to application of multi-target blocking peptide in preventing and treating new coronavirus infection.
Background
It is known that the existing antiviral drugs have limited killing effect on new coronavirus, toxic and side effects are difficult to avoid, and part of mRNA vaccines which are put into use have obvious adverse reaction, even cause death of old infected people, so that the whole process of infecting host cells by the new coronavirus is further disclosed, a new drug action target is discovered, and a novel therapeutic drug is developed to intervene in invasion of the new coronavirus into the host cells, which is the key point of the current research on the new coronavirus, the new coronavirus belongs to a single-chain RNA virus and mainly enters cells after being combined with receptors on host cell membranes through an RBD structural domain of S protein of the new coronavirus, the research and development of the current new coronavirus antibody vaccine mainly focuses on RBD of virus protein, but the neutralizing effect of the current known antibody on the virus can only be maintained for about half a year, and the traditional vaccine can not meet the prevention and treatment requirements of the virus along with weakening of antibody action and rapid mutation of the virus, while the development of safe and effective novel virus neutralizing drugs is continued, safe and effective drugs are searched from receptors of virus infected cells, and a brand new concept and a new hope are brought to the prevention and treatment of the novel coronavirus.
Disclosure of Invention
In order to overcome the defects in the background art, the invention discloses application of multi-target blocking peptide in preventing and treating new coronavirus infection.
Use of multi-target blocking peptides for the prevention and treatment of new coronavirus infections, including multi-target blocking peptides targeting APP, LDLR and LRP, namely: AY51, application of amino acid sequence of multi-target blocking peptide and its modified lysine and C-16 fatty acid in preventing and treating SARS-CoV-2 infection.
The sequence of the multi-target blocking peptide is as follows:
AY 51-1: KKKKKKLKVRLASHLRK [ Glu ] [ C-16] LRKRLLRDA and
AY51-2：KKKKKKLKVALAGHLRK[Glu][C-16]LRKRLLRDA。
the multi-target blocking peptide can block the interaction of SARS-CoV-2-S protein RBD and its receptor, and finally prevent the new coronavirus from invading target cell.
Due to the adoption of the technical scheme, the invention has the following beneficial effects: the invention discloses the amino acid sequence of ApoE LDLR binding domain and the application of modified amino acid and C-16 fatty acid in preventing and treating the infection of novel coronavirus SARS-CoV-2, and simultaneously, the fused polypeptide can efficiently block the interaction of SARS-CoV-2-S protein RBD and various receptors on the cell membrane thereof in a targeted way from molecular, cell and animal levels, and finally the multi-target blocks the virus from invading the target cell to achieve the aim of preventing and treating the infection of the novel coronavirus.
Detailed Description
The present invention will be explained in detail by the following examples, which are disclosed for the purpose of protecting all technical improvements within the scope of the present invention.
Example 1, the application of the multi-target blocking peptide in preventing and treating new coronavirus infection, which is disclosed by the invention, detects that the fused polypeptide can efficiently block the interaction of SARS-CoV-2-S protein RBD and various receptors on the cell membrane thereof in a targeted way from the levels of molecules, cells and animals, and the neutralization inhibition rate of the multi-target blocking peptide in inhibiting pseudovirus infection is shown in the following table:
the concentration of live virus-infected culture cells and half of the tissue culture infectious dose for multi-target blocking peptide were compared as shown in the following table:
while the invention has been particularly shown and described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (3)
1. Use of multi-target blocking peptides for the prevention and treatment of new coronavirus infections, including multi-target blocking peptides targeting APP, LDLR and LRP, namely: AY51, application of amino acid sequence of multi-target blocking peptide and lysine amino acid and C-16 fatty acid modified peptide in preventing and treating novel coronavirus infection.
2. The use of the multi-target blocking peptide of claim 1 for the prevention and treatment of new coronavirus infection, wherein: the sequence of the multi-target blocking peptide is as follows:
AY 51-1: KKKKKKLKVRLASHLRK [ Glu ] [ C-16] LRKRLLRDA and
AY51-2：KKKKKKLKVALAGHLRK[Glu][C-16]LRKRLLRDA。
3. the use of the multi-target blocking peptide of claim 1 for the prevention and treatment of new coronavirus infection, wherein: the multi-target blocking peptide can block the interaction of SARS-CoV-2-S protein RBD and its receptor, and finally prevent the new coronavirus from invading target cell.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110155487.0A CN112999333A (en) | 2021-02-04 | 2021-02-04 | Application of multi-target blocking peptide in preventing and treating new coronavirus infection |
| CN202210091789.0A CN115177714B (en) | 2021-02-04 | 2022-01-26 | Application of multi-target blocking peptide in preparation of medicines for preventing and treating new coronavirus infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110155487.0A CN112999333A (en) | 2021-02-04 | 2021-02-04 | Application of multi-target blocking peptide in preventing and treating new coronavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112999333A true CN112999333A (en) | 2021-06-22 |
Family
ID=76385064
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110155487.0A Pending CN112999333A (en) | 2021-02-04 | 2021-02-04 | Application of multi-target blocking peptide in preventing and treating new coronavirus infection |
| CN202210091789.0A Active CN115177714B (en) | 2021-02-04 | 2022-01-26 | Application of multi-target blocking peptide in preparation of medicines for preventing and treating new coronavirus infection |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210091789.0A Active CN115177714B (en) | 2021-02-04 | 2022-01-26 | Application of multi-target blocking peptide in preparation of medicines for preventing and treating new coronavirus infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN112999333A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114395049A (en) * | 2022-01-06 | 2022-04-26 | 清华大学 | Modified peptide material of targeting SARS-CoV-2S protein RBD, preparation method and application thereof |
| WO2023070036A1 (en) * | 2021-10-20 | 2023-04-27 | Arizona Board Of Regents On Behalf Of Arizona State University | Neutralizing trivalent protein-dna molecules (tri-pdbody) for sars-cov-2 infection treatment |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027963A2 (en) * | 2003-09-15 | 2005-03-31 | The United States Of America As Represented By Thesecretary Of Health And Human Services, Nih | METHODS AND COMPOSITIONS FOR THE GENERATION OF A PROTECTIVE IMMUNE RESPONSE AGAINTS SARS-CoV |
| TWI303249B (en) * | 2004-01-09 | 2008-11-21 | Nat Health Research Institutes | Receptor binding polypeptides |
| CN103554244B (en) * | 2013-05-09 | 2016-09-07 | 香雪集团(香港)有限公司 | There is peptide and application and the preparation method of the activity of suppression respiratory virus infection |
| CN111592594B (en) * | 2020-03-13 | 2022-05-10 | 北京大学 | Monoclonal antibody for resisting novel coronavirus and application thereof |
| CN111825750A (en) * | 2020-05-21 | 2020-10-27 | 谭骏 | Application of ACE2 receptor protective synthetic short peptide in novel coronavirus infection |
| CN111732637B (en) * | 2020-05-25 | 2022-03-01 | 上海交通大学 | Polypeptide for inhibiting novel coronavirus SARS-CoV-2 from infecting host cell and its application |
| CN111617232B (en) * | 2020-06-04 | 2023-04-18 | 安域生物科技(杭州)有限公司 | Application of ApoE receptor protein short peptide blocker in Alzheimer disease |
| CN111632055A (en) * | 2020-07-07 | 2020-09-08 | 李成 | Application of rosuvastatin calcium in preparation of medicine for treating new coronary pneumonia |
| CN112079901B (en) * | 2020-09-04 | 2021-11-19 | 华中科技大学 | Antagonistic polypeptide and application thereof in preparing anti-novel coronavirus medicines |
-
2021
- 2021-02-04 CN CN202110155487.0A patent/CN112999333A/en active Pending
-
2022
- 2022-01-26 CN CN202210091789.0A patent/CN115177714B/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023070036A1 (en) * | 2021-10-20 | 2023-04-27 | Arizona Board Of Regents On Behalf Of Arizona State University | Neutralizing trivalent protein-dna molecules (tri-pdbody) for sars-cov-2 infection treatment |
| CN114395049A (en) * | 2022-01-06 | 2022-04-26 | 清华大学 | Modified peptide material of targeting SARS-CoV-2S protein RBD, preparation method and application thereof |
| CN114395049B (en) * | 2022-01-06 | 2023-10-27 | 清华大学 | Modified peptide material of targeting SARS-CoV-2S protein RBD, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115177714A (en) | 2022-10-14 |
| CN115177714B (en) | 2023-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Virus–host interactions in foot-and-mouth disease virus infection | |
| CN111228483A (en) | Broad-spectrum antibody spray for novel coronavirus and SARS virus | |
| Chen et al. | Innate sensing of viruses by pattern recognition receptors in birds | |
| CN112999333A (en) | Application of multi-target blocking peptide in preventing and treating new coronavirus infection | |
| US10967015B2 (en) | Method of treatment using oncolytic viruses | |
| Ilinskaya | Antiviral activity of binase against the pandemic influenza A (H1N1) virus | |
| US20230348880A1 (en) | Soluble ace2 and fusion protein, and applications thereof | |
| Mechlia et al. | Dermaseptins as potential antirabies compounds | |
| JP2018531578A (en) | Attenuated influenza vectors for prevention and / or treatment of infectious diseases and treatment of neoplastic diseases | |
| Prüβ | Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivity | |
| Liu et al. | The herpesvirus accessory protein γ134. 5 facilitates viral replication by disabling mitochondrial translocation of RIG-I | |
| JP2016520534A (en) | Influenza nucleoprotein vaccine | |
| Hebert et al. | IL-22Ra1 is induced during influenza infection by direct and indirect TLR3 induction of STAT1 | |
| CA3175831A1 (en) | Lipid-peptide fusion inhibitors as sars-cov-2 antivirals | |
| Ahmed et al. | IFN mimetic as a therapeutic for lethal vaccinia virus infection: possible effects on innate and adaptive immune responses | |
| Kwon et al. | The protective effect of Tilia amurensis honey on influenza A virus infection through stimulation of interferon-mediated IFITM3 signaling | |
| Nishikawa et al. | Immune response induced in rodents by anti-CoVid19 plasmid DNA vaccine via pyro-drive jet injector inoculation | |
| Aghamollaei et al. | Emerging Technologies for the Treatment of COVID-19 | |
| He et al. | C-Fiber Degeneration Enhances Alveolar Macrophage-Mediated IFN-α/β Response to Respiratory Syncytial Virus | |
| Sun et al. | Blood brain barrier permeability and immune function of brain in rainbow trout responding to IHNV infection | |
| JP5946453B2 (en) | Mutant rabies virus and vaccine | |
| WO2022000167A1 (en) | Use of transferrin, transferrin receptor and antibody thereof in preparation of drug for resisting sars-cov-2 virus | |
| US20230355740A1 (en) | Compositions and methods of use thereof for prevention and treatment of influenza infections | |
| Huang et al. | Protective efficacy of live attenuated rabies virus against Lethal Challenged Virus Strain (CVS-11) infection in the Central Nervous System (CNS) of mice | |
| Khalil et al. | Antiviral responses versus virus-induced cellular shutoff: a game of thrones between influenza A virus NS1 and SARS-CoV-2 Nsp1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210622 |
|
| WD01 | Invention patent application deemed withdrawn after publication |